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Abstract
Background: Given the limitation of pharmacological treatments to treat cognitive symptoms in patients with
Major Depressive Disorder (MDD), cognitive remediation programs has been proposed as a possible procognitive
intervention but findings are not conclusive. This study investigates the efficacy of an INtegral Cognitive
REMediation (INCREM) that includes a combination of a Functional Remediation (FR) strategy plus a Computerized
Cognitive Training (CCT) in order to improve not only cognitive performance but also the psychosocial functioning
and the quality of life.
Methods: A single blind randomized controlled clinical trial in 81 patients with a diagnosis of MDD in clinical
remission or in partial remission. Participants will be randomized to one of three conditions: INCREM (FR + CCT),
Psychoeducation plus online games and Treatment As Usual (TAU). Intervention will consist in 12 group sessions, of
approximately 110 min once a week. The primary outcome measure will be % of change in psychosocial
functioning after treatment measured by the Functional Assessment Short Test (FAST); additionally, number of sick
leaves and daily activities will also be recorded as pragmatic outcomes.
Discussion: To our knowledge, this is the first randomized controlled clinical trial using a combination of two
different approaches (FR + CCT) to treat the present cognitive deficits and to promote their improvements into a better
psychosocial functioning.
Trial registration: Clinical Trials NCT03624621. Date registered 10th of August 2018 and last updated 24th August 2018.
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Background
Cognitive dysfunction is considered a new treatment
target to improve psychosocial functioning and enhance
the quality of life in patients with Major Depressive
Disorder (MDD) [1, 2]. Previous research suggests that
cognitive symptoms explain the low rates of global
recovery and functional disability [3–5]. In fact, current
pharmacological treatments for MDD have not been
considered useful for the improvement of cognitive
dysfunction probably because they are focused on im-
proving mood [6]. The only antidepressants that seem to
have a potential procognitive impact are duloxetine and
vortioxetine [7–9], but further studies are needed to
clarify these findings.
Regarding non-pharmacological treatments, Cognitive
Remediation (CR) is a psychotherapeutic approach that
has shown improvement in cognition in other neuro-
psychiatric disorders [10, 11] However, only few studies
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have been conducted in MDD patients [12–15]. The
design features of the interventions differ from one
another, making it difficult to demonstrate their efficacy.
Moreover, samples included in CR studies were very
heterogeneous with different disease burden, which
would have impeded conclusions about the specific
effect of CR for MDD. Analyses were also limited by the
fact that not all patients show the same profile of cogni-
tive impairment. It is estimated that 50% of depressed
patients [16, 17] present enduring cognitive deficits,
which would significantly interfere in workplace and in
psychosocial functioning, while another large percentage
of patients do not suffer from cognitive dysfunction.
Apart from that, most of CR programs have been
based on neurological models designed to reverse
cognitive deficits acquired after or associated with
neurological conditions [18, 19], while the focus of CR
programs in psychiatric diseases should be more directed
in improving everyday functioning rather than merely
recovering cognitive losses. Computerized Cognitive
Training (CCT), which is based on cognitive exercises and
games, appears to be, by contrast, an optimal method to
improve cognitive functioning in affective disorders due to
the flexibility given to adjust the tasks to the needs of each
patient. In addition, and according to a recent meta-ana-
lysis [20], CCT improved depressive symptomatology and
everyday functioning in patients with MDD, though pro-
ducing inconsistent effects on cognition.
The scarce evidence on the efficacy of cognitive
interventions may have prevented a broad implementa-
tion of such programs in the clinical setting. Moreover,
research should define how cognitive remediation pro-
grams are to be administered (e.g., number of sessions),
what cognitive domains are to be trained, and how this
intervention can impact on psychosocial functioning.
Therefore, there is a strong need of randomized clinical
trials so as to demonstrate the efficacy of such interven-
tions [14, 15].
Recently, one new ‘ecological’ intervention named
Functional Remediation (FR) has been designed with the
aim of transferring cognitive improvements to the daily
functioning, by using neurocognitive techniques and
training but also through psychoeducation on cognition
and problem-solving. The FR program includes
modeling techniques, role-playing, verbal instructions,
self-instructions, positive reinforcement and meta-cogni-
tive cues using real-life problems [21]. FR in bipolar dis-
order has shown significant enhancement of functional
outcomes as well as subsyndromal symptomatology [22–
24]. This is a group intervention and, thus, it is difficult
to tailor the tasks to the specific needs of each
individual.
Considering the above, the evidence accumulated
indicates that the most adequate intervention to treat
cognitive symptoms in MDD would be a combination of
a group FR plus a personalized CCT. The inclusion of
both aspects will allow the intervention to focus on the
present deficits through the formation of new strategies
with compensatory techniques and promoting their use
into everyday life.
Aims of the study
This study aims to show the efficacy of an INtegral
Cognitive REMediation (INCREM) program specifically-
designed for MDD patients so as to improve psycho-
social functioning through the treatment of cognitive
symptoms.
Primary research aims:
– To develop and to prove the efficacy of INCREM;
this includes a FR program and a CCT.
– To improve psychosocial functioning in MDD patients.
– To decrease the rate of patients with enduring
cognitive symptoms, and to reduce the risk of
further relapses.
Secondary research aims:
– To establish cognitive profiles in MDD patients, to
tailor the Integral Cognitive Remediation therapy so
as to achieve full remission.
– To increase the effect size of the intervention by
combining traditional group sessions plus
computerized individual sessions.
– To study the specific elements (cognitive and
psychosocial aspects) that mediate clinical and
functional improvement, which can be ascertain
through well-being and decrements in cognitive
complaints.
Methods and Design
This is a single blind, randomized controlled clinical trial
approved by the Research Ethics Board of the Hospital
de la Santa Creu i Sant Pau. All participants will receive
extended information about the study and must give
their written informed consent prior to the inclusion.
The study will be carried out in accordance with the
ethical principles of the declaration of Helsinki and
Good Clinical Practices, complying with data protection
laws with the anonymization of all the information
collected (Data Protection Act 2018).
Participants
Patients aged between 18 to 60 years with a diagnosis of
MDD (DSM-5 criteria) will be recruited from the
psychiatry department of the Hospital de la Santa Creu i
Sant Pau in Barcelona (Catalonia, Spain) to participate
in the present study. This center covers a population of
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400.000 inhabitants, and therefore, the recruitment will
be achieved. All patients will have to be in clinical remis-
sion or in partial remission, defined by scores below 14
in the HDRS-17. To be allocated in one of the treatment
arms, patients will have to display objective cognitive
deficits (measured with the Screening for Cognitive
Impairment in Psychiatry – SCIP, defined by a score
below 80) [25, 26] together with psychosocial dysfunc-
tion, defined by a score from 12 to 20 (mildly impaired)
in the FAST [27]. All patients will continue with their
usual pharmacological treatment. Exclusion criteria are:
i) an intelligence quotient (IQ) below 85, ii) any medical
condition that may affect neuropsychological perform-
ance, iii) presence of any comorbid psychiatric condition
including non-nicotine substance use disorders on the
previous three months, iv) having received electrocon-
vulsive therapy on the previous year or psychological
intervention in the previous 6 months.
Study design
Figure 1 provides a schedule of the study. Detailed oral
and written information about the study will be provided
to all potential candidates to participate in the study. If
they are interested in participate, informed consent will
be signed and demographic, clinical, neuropsychological
and functional assessments will be performed by an
experienced clinical neuropsychologist. After the fulfill-
ment of the inclusion criteria, patients will be random-
ized to one of the three possible treatment options:
INCREM program which includes both a FR program
adapted to depression, and a CCT; Psychoeducation plus
online mental skill games; and Treatment as Usual
(TAU). A more detailed explanation of the two active
treatment arms is provided below. An independent
statistician from the Department of Epidemiology
(Hospital de la Santa Creu i Sant Pau) will carry out the
randomization by means of computer-generated random
numbers. In order to ensure balanced sample sizes
across groups over time, a block randomization method
will be used. The block size will be set to 27, so as to
have 9 patients per treatment arm, in 3 consecutive
blocks. Blocks will then be randomly chosen to deter-
mine patients’ final assignment. Another experienced
clinical researcher will assign participants to the corre-
sponding intervention. The psychologists conducting
treatment interventions will be different from the clin-
ical neuropsychologist who will carry out the assess-
ments and who will be blind to the treatment
assignment. The intervention will be discontinued in
case of request by the participant. Any other concomi-
tant psychological treatment will not be permitted
during the trial. Finally, to ensure adherence to interven-
tion, after one unjustified absence rated by the psycholo-
gist, a phone call will be done prior to the next session.
After 3 months of treatment (12 sessions) efficacy
measures will be collected: Functioning Assessment
Short Test (FAST) [28], Perceived Deficit Questionnaire
(PDQ-20) [29, 30], Hamilton Depression Rating Scale
(HDRS-17) [31, 32], Remission from Depression
Questionnaire (RDQ) [33] and 36-Item Short Form
Health Survey, Version 2 (SF-36-V2) [34]. Then, 6
months after the intervention, a complete demographic,
clinical, neuropsychological and functional assessment
will be performed in order to evaluate the eventual long
term effects. To promote retention and interest in the
study by the participants, a detailed report about their
evolution will be provided to them.
Estimation of sample size was set at 27 participants in
each treatment arm, assuming a minimum difference on
6 points on the FAST (primary outcome), and consider-
ing a bilateral significance level of 5% and a statistical
power of 80%, adjusted by a 20% rate of dropouts.
Demographic and clinical assessment
A semi-structured interview will be used to assess
demographic and clinical variables at baseline. Demo-
graphic assessment will include gender, age, years of
education, age at which schooling was completed,
work situation, work adjustment, marital status,
cohabiting characteristics, and the number of children
if any.
The Cognitive Reserve Assessment Scale in Health
(CRASH; in press) will be included so as to estimate
the cognitive reserve. It is a semi-structured
interview-based scale that evaluates three domains
considered fundamental in the construct of cognitive
reserve: education, occupation and intellectual and
leisure activities.
The clinical evaluation will cover age at illness onset,
number of previous episodes, age of first psychiatric
hospitalization, number of hospitalizations, period of
clinical stability, seasonal pattern, presence of rapid cyc-
ling depression, presence of melancholy, atypical depres-
sion and psychotic symptomatology during depression,
comorbidities in axis I, II and III, life history of suicidal
ideation, life history of suicide attempts, number of
attempts, method and medical severity used, and family
history of psychiatric disorders and suicide. The
HDRS-17 will be used to evaluate current depressive
symptoms and assess clinical changes. In addition, the
RDQ will be used to evaluate the patient-perceived
remission that includes subscales for symptoms of de-
pression, other symptoms such as anxiety and irritability,
coping ability, positive mental health, functioning, life
satisfaction and a general sense of well-being. These two
scales will be analyzed as secondary clinical outcomes to
evaluate the possible lasting effects.
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Neuropsychological assessment
Following the clinical assessment, a neuropsychological
battery of tests will be administered by experienced
neuropsychologists at the beginning of the study and at
12 months after intervention. It comprises standardized
tests to assess attention, working memory, verbal and
visual memory, processing speed and executive function.
Premorbid Intelligence will be estimated with Vocabu-
lary and Block Design subtests of the Wechsler Adult
Intelligence Scale version-IV (WAIS-IV) [35]. Attention
and verbal working memory performance will be evalu-
ated with Digit forward and backward (WAIS-IV). The
Conners Continuous Performance Test 3rd Edition
(CPT-III) [36] will be used to assess sustained attention.
Verbal learning memory will be measured by the
California Verbal Learning Test (CVLT) [37]. Copy and
recall of the Rey-Osterrieth Complex Figure (ROCF)
[38] will be used to evaluate visuoconstructive abilities
and visual memory. Processing speed will be measured
by the Digit Symbol Substitution Test (DSST;
WAIS-IV) and the Trail Making Test Part A
(TMT-A) [39]. Finally, executive functioning will be
measured with the Trail Making Test Part B (TMT-B)
[39], the Stroop Color and Word Test (STROOP)
[40], the Wisconsin Card Sorting Test (WCST) [41],
the Tower of London (TOL) [42] and the Category
Fluency and PMR (adapted for Spanish speaking
population) [43, 44]. TMT-B is used to evaluate
set-shifting abilities, STROOP interference is used to
evaluate difficulties with response inhibition, WCST
assess abstract reasoning ability and the ability to
shift cognitive strategies in response to changing
environmental contingencies, TOL is used to detect
deficits in planning and problem-solving and Category
Fluency and PMR are used to measure semantic and
phonemic verbal fluency, respectively.
Fig. 1 Schedule of enrolment, interventions, and assessments
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Intervention
Selected patients are going to be randomized to three
possible intervention arms: INCREM; PSYCHOEDUCA-
TION + online games; and Treatment as Usual (TAU).
INCREM will consist of 12 sessions, of approximately
110min once a week, involving a FR and a CCT. FR pro-
gram was originally developed for bipolar patients [45] and
it will be adapted for depressed patients creating a more in-
tensive program focused on executive functions, memory
and attention. The sessions aim at improving daily func-
tioning based on ecological tasks where they need to use
compensatory techniques. The specific explanation of the
sessions is developed in Table 1. CCT will be applied right
after FR group sessions in individual computer sessions
during 20min. The modules of training will be facilitated
by the licensed game-like software CogniFit (https://www.
cognifit.com). This neurocognitive stimulation program
consists of a battery of tasks that allows depressed patients
to improve their cognitive skills depending on their individ-
ual performance throughout different activities.
PSYCHOEDUCATION will consist of 12 sessions, 90
min once a week involving psychoeducation sessions
plus 20 min online non-directed game playing. This
treatment arm has been designed as the control inter-
vention arm due to its beneficial effects for depression.
The material for the psychoeducation intervention has
been specifically designed for the study and is based on
validated treatment protocols [46–48]. Information
about the disease is provided during the sessions so as
to gain knowledge and strategies to cope with their own
difficulties and to improve their quality of life. Therefore,
the intervention will be divided in two modules: the first
module (sessions 1 to 4) will consist in providing
information about the disease and its treatment, and the
second one (sessions 5 to 12) will consist of introducing
different cognitive-behavioral techniques that have proven
to be effective for depression. The specific explanation of
the sessions is developed in Table 2. The online game will
be applied right after the psychoeducation sessions during
20min. The games will be facilitated by a free mini-game
online website (www.frivplus.com). No records will be
gathered on this last part, as it is only used to make com-
parable the two active treatment arms.
TAU will consist in giving the usual treatment to
patients according to accepted standards for depres-
sion (except psychotherapy which will not be allowed
6 months before the study nor during it).
Outcome measures
The primary outcome measure of the study will be the
change in psychosocial functioning after treatment, which
will be measured by means of the FAST. The FAST is a
scale created to assess disability in functioning in mental
health which contains 24 items evaluating autonomy,
occupational functioning, cognitive functioning, financial
issues, interpersonal relationships and leisure time. The
scores range from 0 to 72, with higher scores indicating a
greater disability. A sum of ≥12 represents a mildly to
severe functional impairment in patients with bipolar
disorder [27]. Given the complexity of the possible effects
of the intervention, changes in pragmatic variables of
psychosocial functioning will also be evaluated: number of
sick leaves and number of daily activities.
Table 1 Content of the 12-week Functional Rehabilitation
Program
Session Topics Covered
1. What is attention? (I) Strategies of concentration
2. What is attention? (II) Strategies to improve attention
3. Reading Recovering the habit of reading
4. What is memory? (I) Mnemonic strategies
5. What is memory? (II) The use of diaries and external
aids
6. What are executive functions? (I) Self-instructions
7. What are executive functions? (II) Programing activities, prioritization
and time management
8. What are executive functions? (III) Problem solving strategies
9. What are executive functions? (IV) Working memory strategies
10. Stress Stress and neurocognition
11. Communication Communication skills and
assertiveness
12. Autonomy Independence and autonomy
Table 2 Content of the 12-week Psychoeducational Program
Session Topics Covered
1. What is depression? (I) Concept of depression
2. What is depression? (II) Definition, symptoms, prevalence
and course
3. Etiology of depression Biopsychosocial model, psychobiology
and psychological theories
4. Treatment of depression Pharmacological, psychological and
other treatment options
5. Behavioral Activation (I) Introduction to Behavioral Activation
6. Behavioral Activation (II) Exposition to positive activities
7. Cognitive Distortions Cognitive distortions, automatic
negative thoughts and cognitive
restructuring technique
8. Anxiety Anxiety management strategies
9. Social Skills (I) Social skills deficits and
communicational styles
10. Social Skills (II) Social skills training
11. Problem-Solving
Technique
Problem-Solving training
12. Relapse Prevention Summary of the sessions and relapse
prevention
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Different secondary outcome measures will be
analyzed: i) the change in cognitive performance across
cognitive domains (through composite scores of the
different cognitive domains and a global composite
cognitive score); ii) change in subjective appraisal of cog-
nitive functioning evaluated with the PDQ-20 which is a
self-reported questionnaire that measures the patients’
perception of their cognitive functioning. It consists of
20 items assessing attention, retrospective memory,
prospective memory, and planning and organization; iii)
change in depressive symptoms with the HDRS-17); iv)
change in patients’ perspective of clinical remission with
the RDQ; and v) change in quality of life assessed with
the SF-36-V2. It evaluates the patients’ health-related
quality of life gauging eight sections: vitality, psychical
functioning, bodily pain, general health perceptions,
physical role functioning, emotional role functioning,
social role functioning and mental health.
Statistical analysis plan
Data will be collected in three different moments: baseline,
post-intervention and follow-up through a logbook data
collection. Then, an online application called Clinapsis will
be used for data collection, which ensures anonymisation
of data (through encoding system). This system will grant
public access to the full protocol and dataset at
participant-level for further analysis beyond this proposal.
The data will be analyzed using the Statistical Package
of Social Sciences (SPSS, IL, Chicago, version 20) and R
Package (version 3.1.2). First, baseline differences be-
tween groups will be investigated using chi-square tests
and ANOVAs depending on the nature of the variables.
Secondly, mixed-models will be carried out to assess the
impact of the three different treatment options on the
psychosocial functioning scores assessed with the FAST
scale (primary outcome measure). Effect sizes of inter-
ventions will be calculated. Secondary variables will also
be analyzed with the same statistical approach. Mixed
repeated measures ANOVAs will be carried out to inves-
tigate the long-term effects of interventions on second-
ary outcomes. Finally, in order to investigate predictors
of treatment response, a study of mediators and modera-
tors will be conducted. For the main statistical analysis,
the Last Observation Carried Forward method will be
used to minimize the effect of dropout rates at 6 months
of follow-up after intervention.
Discussion
Cognitive impairment is nowadays considered a core
symptom of MDD and a critical determinant of psycho-
social and workplace outcomes, as well as health outcomes
such as the health-related quality of life. CR has been used
to treat these cognitive deficits suggesting significant
improvements in cognition but with small effect sizes for
psychosocial functioning. This study aims to improve
psychosocial functioning through the improvement in
cognitive performance. To our knowledge, this is the first
randomized clinical trial using an INtegral Cognitive
REMediation (INCREM) composed by 12 sessions of a FR
program and a CCT.
The major strength of this study is the combination of
two different approaches at the same time: a group
format therapy together with a computerized program
that allows a personalized delivery of the intervention.
This synergistic approach may represent the path to
optimize treatment response and ensure better func-
tional outcomes in patients with MDD. The presence of
an active control group beyond treatment as usual
(TAU) is another relevant strength of the study. A large
battery of primary and secondary outcome measures will
be used to evaluate the efficacy of the intervention. Pa-
tients will be approached six months after finishing the
intervention to assess the maintenance of possible
changes. Furthermore, this study will take into account
the specific cognitive deficits of each patient by adapting
CCT to individual performance.
A potential limitation of the present study is inherent
to any clinical trial, given that participation and
follow-up of the interventions could be more compli-
cated. A 20% of dropouts are calculated throughout the
intervention and/or follow-up has been estimated, but
this percentage could be higher, which would limit the
power of the analysis. Patients should be in remission or
in partial remission with cognitive deficits and difficul-
ties in daily life, so that recruitment and inclusion might
be more complicated. Concomitant medication might
also represent a possible limitation because of side ef-
fects or even procognitive effects of newer drugs. Medi-
cation regimes will be recorded during the different
phases of the study and then will be taken into account
in the analyses. In any case, in the clinical practice, poly-
medicated patients are the rule rather than the excep-
tion. Hence, it might limit internal validity but it is
strength for the generalization of the results.
Conclusion
The presence of residual cognitive symptoms, observed
in the clinical settings, may impede the achievement of
full remission in patients with depression. Therefore, ef-
fective cognitive treatments are an unmet need. If the re-
sults of this study are conclusive, the INCREM could be
added to the therapeutic arsenal for depression. This
non-pharmacological treatment may seem expensive as
it consists in 12 sessions, but if one considers the direct
and indirect social and healthcare costs of depression
[49], then targeting cognitive symptoms with a cognitive
program will likely be cost-effective.
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